Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BIOCON LTD. - 532523 - Compliance Certificate Under Regulation 40(9) For The Half Year Ended September 30, 2020.

 Dear Sir/Madam, With reference to the above subject, please find enclosed the Half Yearly Compliance Certificate under Regulation 40(9) of SEBI Listing Regulations, issued by Mr. Pradeep B Kulkarni, Practicing Company Secretary with regard to transfer/ sub-division/ consolidation/ renewal/ exchange or endorsement of calls/ allotment of monies for the half year ended September 30, 2020.
13-10-2020

Forbes India Rich List 2020: A look at 5 wealthiest women and their net worth

 Biocon's Kiran Mazumdar-Shaw is the highest percentage gainer, not just amongst women but the 100 richest persons listed by Forbes.
09-10-2020
Bigul

BIOCON LTD. - 532523 - Shareholding for the Period Ended September 30, 2020

 Biocon Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here
09-10-2020

Biocon Foundation to contribute Rs 65 crore for Metro station construction in Bengaluru

 The MoU was inked by Biocon Foundation Founder and Managing Trustee Kiran Mazumdar-Shaw and BMRCL Director Ajay Seth.
08-10-2020
Bigul

BIOCON LTD. - 532523 - Biocon Foundation Signs Mou With Bangalore Metro To Contribute Towards Building Metro Station In Hebbagodi.

 Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi.
08-10-2020
Bigul

BIOCON LTD. - 532523 - Board Meeting Intimation for To Approve And Take On Record The Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2020 Amongst Other Routine Matters.

 BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/10/2020 ,inter alia, to consider and approve the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2020 amongst other routine matters. The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from October 1, 2020 to October 24, 2020 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations.
06-10-2020
Bigul

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

 With phase 4 clinical trials now on, the sales may see a further uptick if data supports its use on Covid-19 patients, said experts.
05-10-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
30-09-2020
Bigul

Biocon to roll out phase-4 post-marketing surveillance for Itolizumab to treat Covid-19 patients

 Biopharmaceuticals major, Biocon Ltd, is set to roll out the phase-4 post-marketing surveillance for its repurpose drug Itolizumab to treat Covid-19 p
29-09-2020
Bigul

BIOCON LTD. - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Investor Meeting
25-09-2020
Next Page
Close

Let's Open Free Demat Account